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Abstract
Aims/hypothesis Salt-inducible kinases (SIKs) are related to
the metabolic regulator AMP-activated protein kinase
(AMPK). SIK2 is abundant in adipose tissue. The aims of this
study were to investigate the expression of SIKs in relation to
human obesity and insulin resistance, and to evaluate whether
changes in the expression of SIKsmight play a causal role in the
development of disturbed glucose uptake in human adipocytes.
Methods SIK mRNA and protein was determined in human
adipose tissue or adipocytes, and correlated to clinical vari-
ables. SIK2 and SIK3 expression and phosphorylation were
analysed in adipocytes treated with TNF-α. Glucose uptake,
GLUT protein levels and localisation, phosphorylation of pro-
tein kinase B (PKB/Akt) and the SIK substrate histone
deacetylase 4 (HDAC4) were analysed after the SIKs had
been silenced using small interfering RNA (siRNA) or
inhibited using a pan-SIK-inhibitor (HG-9-91-01).
Results We demonstrate that SIK2 and SIK3mRNA are down-
regulated in adipose tissue from obese individuals and that the
expression is regulated by weight change. SIK2 is also nega-
tively associated with in vivo insulin resistance (HOMA-IR),
independently of BMI and age. Moreover, SIK2 protein levels
and specific kinase activity display a negative correlation to
BMI in human adipocytes. Furthermore, SIK2 and SIK3 are
downregulated by TNF-α in adipocytes. Silencing or inhibiting
SIK1–3 in adipocytes results in reduced phosphorylation of
HDAC4 and PKB/Akt, less GLUT4 at the plasma membrane,
and lower basal and insulin-stimulated glucose uptake in
adipocytes.
Conclusion/interpretation This is the first study to describe
the expression and function of SIKs in human adipocytes.
Our data suggest that SIKs might be protective in the devel-
opment of obesity-induced insulin resistance, with implica-
tions for future treatment strategies.
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Introduction
The salt-inducible kinases (SIKs)—SIK1, SIK2 and SIK3—
are related to AMP-activated protein kinase (AMPK), a master
regulator of cellular and whole body energy homeostasis [1].
AMPK and AMPK-related kinases share sequence homology
in their kinase domains [2] and are all activated by liver kinase
B1 (LKB1) [3]. SIK1 was first identified in the adrenal glands
of rats fed a high salt diet [4] and has since been described in
several cell types [5–8]. SIK2 is highly expressed in adipose
tissue and increases during adipocyte differentiation [9–11],
while SIK3 displays a more ubiquitous expression [12].
Together SIKs control diverse cellular processes including
the regulation of glucose and lipid metabolism in rodent liver
[13–18] and adipose tissue [10, 19, 20]. Recently, it was
shown that mice with global SIK2 deficiency display multiple
defects in adipocyte metabolism [20]. Moreover, a previous
study described increased expression and activity of SIK2 in
white adipose tissue (WAT) from obese db/db mice [9], sug-
gesting a role for SIK2 in obesity and diabetes. SIK3 has also
been linked to metabolism, and Sik3-/- mice display disturbed
lipid and glucose homeostasis [14, 17]. Furthermore, genetic
variations in SIK3 have been associated with dyslipidaemia
and obesity in humans [21].
SIKs regulate gene expression by controlling the phosphor-
ylation of transcriptional regulators, such as class II histone
deacetylases (HDACs) [6, 22] and cAMP-response element
binding protein (CREB)-regulated transcription co-activators
(CRTCs) [23, 24]. This has, so far, mainly been studied in the
liver but we recently demonstrated that HDAC4, CRTC2 and
CRTC3 are direct substrates of SIK2 in rodent adipocytes
[19]. In addition to the activating phosphorylation by LKB1,
SIK2 is phosphorylated at several residues—Ser343, Ser358,
Thr484 and Ser587—in response to cAMP/protein kinase A
(PKA)-signalling in adipocytes, resulting in a subcellular
relocalisation of SIK2 without altering kinase activity [19,
25]. Similarly, SIK3 is phosphorylated at several residues in
response to cAMP/PKA in adipocytes [26].
The biological role of SIK2 in adipocytes is not fully un-
derstood and has almost exclusively been studied in rodents.
Based on these studies, SIK2 appears to be required for
GLUT4 expression and glucose uptake in adipocytes [19,
20]. Therefore, the aim of our study was to investigate the
expression of SIKs, in particular SIK2, in adipose tissue from
healthy and obese or insulin-resistant humans, and to analyse
the importance of SIKs for glucose uptake in human
adipocytes.
Methods
Clinical cohorts Three different cohorts were used. Cohort 1
was used for SIK2 and SIK3 mRNA expression analysis in
subcutaneous WAT and consisted of 56 individuals; of which,
the 37 obese participants underwent gastric bypass surgery
and 19 were non-obese controls [27]. Briefly, participants
came to the laboratory after overnight fasting. Height, weight
and waist circumference were measured and BMI calculated.
Venous blood samples were collected for analysis of glucose,
insulin, triacylglycerol and cholesterols [28]. An abdominal
subcutaneous adipose tissue biopsy was taken as previously
described [29]. In vivo insulin resistance was assessed by
hyperinsulinaemic–euglycaemic clamp [30] and HOMA-IR
calculated with the following formula: (glucose [mmol/l] ×
insulin [pmol/l])/405. Participants who underwent gastric by-
pass surgery were examined preoperatively and two years post
surgery. Cohort 2 was used for protein and kinase activity
analysis, and absolute quantification of SIKmRNA in primary
adipocytes. This cohort consisted of 23 individuals who
underwent laparoscopic cholecystectomy or gastric bypass
surgery. Subcutaneous adipose tissue was excised at the be-
ginning of surgery, when at least 1 cm2 of adipose tissue was
retrieved from the edge of the major omentum using
diathermia. Cohort 3 was used for SIK1 mRNA expression
analysis by microarray [31]. Cohorts 1 and 2 are described
in Tables 1 and 2, respectively.
Ethics All participants were given written and oral informa-
tion about the study before providing their written informed
consent. Human studies were approved by the Regional
Ethical Review Boards at Karolinska Institutet and Lund
University. Animal experiments were approved by the
Regional Ethical Committee on Animal Experiments in
Malmö/Lund.
Isolation of primary human adipocytes Human adipocytes
were isolated from subcutaneous or omental (cohort 2) adi-
pose tissue by collagenase digestion. Isolated cells were then
lysed and homogenised as described in detail in the ESM
Methods.
Cell culture and treatments 3 T3-L1 fibroblasts were obtain-
ed from ATCC (Manassas, VA, USA) and cultured and differ-
entiated to adipocytes [32]. Human mesenchymal stem cells
(hMSCs) were isolated from adipose tissue, cultured and dif-
ferentiated in vitro as described previously [27]. Fully differ-
entiated adipocytes were treated with mouse or human TNF-α
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(Sigma-Aldrich, St Louis, MO, USA), or a pan-SIK-inhibitor
(HG-9-91-01, kindly provided by K. Clark, MRC Protein
Phosphorylation Unit, University of Dundee, Dundee, UK
[23]), or electroporated with siRNA [33]. In single siRNA
treatments, 13 nmol/l of specific and 27 nmol/l of non-
targeting siRNA were used to keep the final siRNA concen-
tration at 40 nmol/l. After treatments (concentrations and time
points are indicated in figure legends), cells were lysed in
QIAzol (Qiagen, Hilden, Germany) for gene expression
analysis, or harvested for protein analysis [25]. The siRNA
used are listed in the ESM Methods.
Gene expression analysis Extraction of total RNA, comple-
mentary DNA (cDNA) synthesis and real-time RT-PCR
(qRT-PCR) was performed as described in detail in the ESM
Methods. The primers and DNA oligos used are listed in the
ESM Methods. For SIK2 and SIK3 mRNA expression
analysis (cohort 1), the samples were numerically coded and
all were analysed on the same PCR plate in a randomised
order.
Western blotting and protein analysis Lysates (5–20 μg
protein) were analysed by SDS-PAGE and western blotting
[32]. The antibodies used are listed in the ESM Methods. For
analysis of SIK2 protein levels in primary human adipocytes
(cohort 2), signals were normalised to β-actin [34] as well as
to an internal control sample loaded in the outer wells of each
gel, and expressed as fold relative to one individual. The sam-
ples were run on gels twice, loaded in randomised orders with
regards to BMI.
In vitro kinase assay Lysates (adipocytes 10–20 μg protein,
adipose tissue 100–200 μg protein) were incubated with SIK2
or SIK3 antibodies coupled to protein G-Sepharose (GE
Healthcare, Little Chalfont, UK), and phosphotransferase ac-
tivity towards the peptide substrates HDAC5tide or
Sakamototide (200 μmol/l, GL Biochem, Shanghai, China)
was measured as described previously [25, 32]. One unit of
activity (U) was defined as that which catalysed the transfer of
1 nmol 32P/min to the substrate.
Glucose transport Basal and insulin-stimulated uptake of
[3H]-glucose was measured as described previously [27, 33]
after siRNA silencing of SIKs for 96 h, or treatment with
HG-9-91-01 as indicated in figure legends.








A vs B A vs C
Age (years) 44 ± 9 46± 9 47± 11 0.307
BMI (kg/m2) 42.3 ± 4.8 28.3 ± 4.5 24.7 ± 2.2 <0.001 <0.001
Waist circumference (cm) 129 ± 10.8 95.5 ± 12.6 86± 7.0 <0.001 <0.001
Waist-to-hip ratio 1.00 ± 0.06 0.92 ± 0.07a 0.87 ± 0.06 <0.001 <0.001
P-glucose (mmol/l) 5.7 ± 1.5 4.9 ± 0.6b 5.0 ± 0.4 <0.001 0.025
P-insulin (pmol/l) 16.5 ± 9.31 4.63 ± 1.87c 3.88 ± 1.57 <0.001 <0.001
P-triacylglycerols (mmol/l) 1.63 ± 0.81d 1.01 ± 0.49 0.92 ± 0.63 <0.001 <0.001
Total cholesterol (mmol/l) 4.8 ± 0.9 4.2 ± 0.9 5.0 ± 1.2 <0.001 0.729
HDL-cholesterol (mmol/l) 1.1 ± 0.2 1.5 ± 0.4 1.6 ± 0.4 <0.001 <0.001
LDL-cholesterol (mmol/l) 3.3 ± 0.8e 2.5 ± 0.7 3.1 ± 1.0f <0.001 0.112
ApoA-I (g/l) 1.20 ± 0.19 1.42 ± 0.33 1.45 ± 0.23 <0.001 <0.001
ApoB (g/l) 0.95 ± 0.24 0.81 ± 0.21 0.90 ± 0.28 0.001 0.363
Clamp (mmol glucose kg−1 body weight min−1) 0.0202 ± 0.0066g 0.0369 ± 0.0075b 0.0439 ± 0.0090 <0.001 <0.001
HOMA-IR 4.30 ± 2.93 1.00 ± 0.43b 0.85 ± 0.37b <0.001 <0.001
Subjects (n) 37 37 19
Data represent value ± SD
a n= 36; b n= 33; c n= 32; d n= 36; e n= 36; f n = 18; g n= 33
Apo, apolipoprotein; P, fasting plasma
Table 2 Characteristics of cohort 2
Non-obese Obese All
Age (years) 54 ± 12.4 43± 11.2a 45± 12.4b
BMI (kg/m2) 25 ± 3.0 42± 9.6 39± 11.2
Sex, male (female) 3 (2) 4 (15) 7 (17)
Subjects (n) 5 19 24
Data represent value ± SD
a n= 15; b n= 20
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Immunofluorescence and total internal reflection fluores-
cence-imaging Primary adipocytes were isolated from male
Sprague Dawley rats as described [32], suspended in
KRB-HEPES (10% vol./vol.), pre-treated with HG-9-91-01
and stimulated with insulin for 5 min. Cells were then washed,
fixed and stained, and subjected to total internal reflection
fluorescence (TIRF)-imaging as described in detail in the
ESM Methods.
Statistical analysisAll values are presented as means (± SD).
Data that were not normally distributed were logarithmically
(log10) transformed. Statistical tests were performed using
GraphPad Prism 6 (La Jolla, CA, USA) or SPSS (IBM,
Armonk, NY, USA). Details of the statistical tests performed
are provided in figure legends.
Results
SIK2 is the dominant SIK in human adipocytes To eluci-
date expression levels of each SIK isoform in human adipo-
cytes, we performed absolute quantification of SIK mRNA
transcripts using gene-specific DNA oligos in two different
human adipocyte models. As shown in Fig. 1, SIK2was clear-
ly the most abundant isoform relative to SIK1 and SIK3. In
order to estimate the contribution of each isoform to total SIK
activity, we performed in vitro kinase assays of SIK2 and
SIK3 in human adipose tissue or adipocyte lysates. This again
suggested that SIK2 is the dominant isoform but that the con-
tribution of SIK3 to total SIK activity is higher than anticipat-
ed from the mRNA expression analysis (ESM Fig. 1a,b). Due
to the lack of specific immunoprecipitating antibodies we
were not able to do the corresponding analysis for SIK1.
Expression of SIK2 and SIK3 mRNA is regulated by
weight change and correlates negatively to insulin resis-
tance Considering the proposed roles of SIK2 and SIK3 in
the regulation of lipid metabolism [9, 17, 20, 21], we analysed
the mRNA expression of these SIK isoforms in subcutaneous
WAT from non-obese and obese women (cohort 1). The ex-
pression of SIK2 and SIK3 was significantly lower in adipose
tissue from obese compared with non-obese individuals
(Fig. 2a, b). Moreover, SIK2 and SIK3 were increased in re-
sponse to weight loss in previously obese individuals
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Fig. 1 SIK2 is the dominant SIK in human adipocytes. Absolute levels of
SIKmRNA in human adipocytes differentiated in vitro (pooled from three
passages), and primary human adipocytes isolated from subcutaneous
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Fig. 2 Expression of SIK2 and SIK3 mRNA is regulated by weight
change and correlates negatively to insulin resistance. Expression of
SIK2 and SIK3 in subcutaneous WAT (cohort 1, BMI 20–55 kg/m2).
LRP10was used as reference gene and the sample with lowest expression
as calibrator. (a) SIK2 and (b) SIK3 mRNA expression in non-obese
(white triangles, n= 19) and obese (black circles, n= 37 and n= 36, re-
spectively) individuals. Statistical significance determined by two-tailed
unpaired Student’s t test. (c) SIK2 (n= 35) and (d) SIK3 (n = 33) mRNA
expression before (black circles) and after weight loss (2 years after
bariatric surgery, black triangles) in obese individuals. Statistical signifi-
cance determined by two-tailed paired Student’s t test. (e) SIK2 (n= 56)
and (f) SIK3 (n = 55) mRNA expression plotted against HOMA-IR.
Correlations made using Pearson correlation test. One outlier in (a, b, e,
f) was excluded from statistical analysis due to deviant raw CT values of
the reference gene (4.5 SD higher than the average CT value) that is
believed to be due to a technical error. *p< 0.05, ***p< 0.001
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association with in vivo insulin resistance, measured by
HOMA-IR (Fig. 2e; r=−0.76, p<0.001). This finding was
independent of BMI and age of the individuals (beta coeffi-
cient −0.45, p=0.006). SIK3 was also negatively associated
with HOMA-IR (Fig. 2f; r=−0.47, p=0.0004) but did not
remain so after adjusting for BMI and age. Additionally, we
analysed the expression of SIK1mRNA in subcutaneousWAT
(cohort 3, [31]) and found that SIK1, in contrast to SIK2 and
SIK3, displayed a higher expression in obese than in non-
obese individuals (ESM Fig. 1c).
SIK2 protein levels and kinase activity are downregulated
in human obesity Based on the observation that SIK2 was
most distinctly affected in human obesity, we chose to mainly
focus our further studies on this isoform. SIK2 protein levels
were determined by western blotting in primary human adi-
pocytes (cohort 2, Fig. 3a). As shown in Fig. 3b, SIK2
displayed a negative correlation to BMI in subcutaneous
adipocytes (r=−0.55, p=0.006). Similarly, SIK2 kinase ac-
tivity was negatively correlated to BMI (Fig. 3c; r=−0.47,
p=0.03). Although we observed a strong positive correlation
between SIK2 kinase activity and protein levels (ESMFig. 2a;
r= 0.98, p < 0.001), the kinase activity in relation to the
amount of SIK2 protein (specific activity) was also negatively
correlated to BMI (ESM Fig. 2b; r=−0.52, p=0.01). There
was no significant association between SIK2 and BMI in
omental adipocytes (ESM Fig. 2c). However, paired analysis
of subcutaneous and omental adipocytes from the same indi-
vidual revealed that SIK2 protein levels in these depots were
similar (ESM Fig. 2d) and co-varied (ESM Fig. 2e; r=0.72,
p=0.006).
SIK2 and SIK3 are downregulated by TNF-α in adipo-
cytes To investigate whether the inflammation often associat-
ed with obesity and insulin resistance [35, 36] influences the
expression of SIK isoforms, adipocytes were treated with
TNF-α. As shown in Fig. 4a, the expression of SIK2 mRNA
decreased in a dose-dependent manner in human adipocytes,
and was reduced by 40% after 6 h (Fig. 4b). Moreover, SIK2
protein displayed a marked dose- and time-dependent reduc-
tion in 3T3-L1 adipocytes (Fig. 4c,d). Similar to SIK2, the
protein levels of SIK3 were also reduced although at a slower
rate (ESM Fig. 3a, b). Furthermore, acute treatment (<3 h)
with TNF-α did not change the kinase activity (ESM
Fig. 3c) or the specific phosphorylation of SIK2 on Ser343,
Ser358 or Thr484 (ESM Fig. 3d–f). The phosphorylation of
mitogen-activated protein kinase (MAPK) p38, a target for
TNF-α signalling [37], was analysed to confirm the activity
of TNF-α, and the expression of the adipocyte marker adipose
triacylglycerol lipase (ATGL) was analysed to exclude any
non-specific effects of the treatment (ESM Fig. 3g).
SIKs promote glucose uptake in human adipocytes and
influence insulin signalling and GLUT4 localisation Since
SIK2 has been shown to promote glucose uptake in rodent
adipocytes [19, 20], we investigated the impact of reduced
expression/activity of SIK isoforms on this process in human
adipocytes. We silenced all three SIK isoforms individually or
simultaneously, as well as employed the highly selective pan-
SIK-inhibitor HG-9-91-01 [23]. The level of SIK1mRNAwas
very low compared with SIK2 (data not shown) and was only
reduced to a modest degree by siRNA (siSIK1, ESM Fig. 4a).
At protein level, there was no effect of siSIK1 (ESM Fig. 4b)
and this condition was thus excluded in further analyses.
Treatment with siRNA against SIK2 (siSIK2) or SIK3
(siSIK3) caused efficient silencing of mRNA and protein ex-
pression (ESM Fig. 4c–f). Silencing of SIK3 was accompa-
nied by a slight increase in SIK2 mRNA (ESM Fig. 4c) but
SIK2 protein was unchanged (ESMFig. 4d). However, silenc-
ing of SIK2 was associated with compensatory upregulation









































































Fig. 3 SIK2 protein levels and kinase activity are downregulated in
human obesity. SIK2 protein levels determined in (a), and kinase activity
in subcutaneous adipocytes from non-obese (white triangles) and obese
(black circles) individuals (cohort 2, BMI 21–66 kg/m2). (a) SIK2 protein
levels. β-actin was used as loading control and its expression did not
change with BMI (ESM Fig. 2f). Graph shows means + SD from two
independent gel runs. Each bar represents one individual and representa-
tive blots are shown below the graph (n= 23). (b) SIK2 protein levels
plotted against BMI (n = 23). (c) SIK2 in vitro kinase activity against the
peptide substrate HDAC5tide plotted against BMI (n= 22). Correlations
made using Pearson correlation test
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presence of residual SIK activity when silencing SIK2 was
demonstrated by a modest reduction in p-HDAC4, an SIK
substrate whose phosphorylation we used as a readout for total
SIK activity (Fig. 5a). Silencing of SIK3 resulted in a larger
reduction in p-HDAC4, and simultaneous silencing of
SIK1–3 (siSIK1+2+3, Fig. 5a) or pan-SIK inhibition
(Fig. 5b) reduced p-HDAC4 even further. Neither basal
(Fig. 5c) nor insulin-stimulated (Fig. 5d) glucose uptake was
changed in siSIK2-treated adipocytes compared with controls.
Silencing of SIK3 was associated with lower basal glucose
uptake (Fig. 5c) and siSIK1+2+3, or overnight SIK inhibition,
resulted in significantly lower glucose uptake both in the ab-
sence and presence of insulin (Fig. 5c–e).
To get insight into mechanisms underlying the effect of
SIKs on glucose uptake we monitored the expression of glu-
cose transporters. We observed an increase in GLUT4 protein
levels following silencing of SIK3 or all three isoforms simul-
taneously (ESM Fig. 5a) and siSIK2 induced GLUT1 (ESM
Fig. 5b). Based on the observation that the positive effect of
SIKs on glucose uptake is not likely to be mediated by chang-
es in GLUT1 and GLUT4 levels we investigated the hypoth-
esis that SIKs promote glucose uptake by directly stimulating
insulin signalling and/or GLUT4 localisation. Consequently,
we treated adipocytes with HG-9-91-01 for 1 h and analysed
glucose uptake. Similar to overnight treatment (Fig. 5e), 1 h of
SIK inhibition was sufficient to lower both basal glucose up-
take and uptake stimulated by sub-maximal (1 nmol/l) and
maximal (10 nmol/l) doses of insulin in human adipocytes
(Fig. 5f). Correspondingly, the amount of GLUT4 close to
the plasma membrane was reduced in rat adipocytes, both in
the basal state and in the presence of sub-maximal insulin
(0.1 nmol/l) (Fig. 5g). Furthermore, pan-SIK inhibition in hu-
man adipocytes was associated with a marked reduction of the
insulin-induced phosphorylation of protein kinase B
(PKB/Akt), a key regulator of GLUT4 translocation [38,
39], at both Thr308 (Fig. 5h) and Ser473 (Fig. 5i).
Discussion
This study is the first to demonstrate SIK expression and func-
tion in human adipose tissue. We have shown that SIK2 and
SIK3 are markedly downregulated in adipose tissue from
obese or insulin-resistant humans (independently of BMI or
age for SIK2) and that the expression is regulated in response
to weight change and inflammation (TNF-α). Moreover, SIKs
promote insulin signalling, GLUT4 translocation to the plas-















































































































































Fig. 4 SIK2 is downregulated by
TNF-α in adipocytes. SIK2
mRNA expression in human
adipocytes differentiated in vitro,
treated with (a) increasing
concentrations of TNF-α for 24 h
and (b) TNF-α 50 ng/ml (black
bars) or vehicle (white bars) for
indicated time points (n= 3
independent experiments
performed in duplicate). 18S
rRNAwas used as reference gene.
(c) SIK2 protein levels in 3T3-L1
adipocytes treated with TNF-α
10 ng/ml (grey bars) or 50 ng/ml
(black bars), or vehicle (white
bars) for indicated time points
(n = 3 independent experiments).
(d) Representative blots with
mean values for relative protein
levels below. β-Actin and heat
shock protein 90 (HSP90) were
used as loading controls.
Statistical significance
determined by two-way ANOVA
with Tukey’s (a, c) or Sidak’s (b)
multiple comparisons post hoc
tests. **p < 0.01, ***p< 0.001,
and †p< 0.05, ††p< 0.01 TNF-α
10 ng/ml vs 50 ng/ml
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Our study demonstrates that interspecies differences exist
in the regulation of SIK2 expression and activity in WAT.
In contrast to what was previously reported in obese mice
[9], we found that SIK2 expression (mRNA and protein)
and activity in adipose tissue and adipocytes were down-
regulated in human obesity. As adipose tissue inflammation
is a key feature of obesity and insulin resistance [35, 36],
we hypothesised that SIK expression is regulated by the
inflammatory cytokine TNF-α. Indeed, both SIK2 and
SIK3 were rapidly downregulated by TNF-α. The molecu-
lar mechanisms mediating transcriptional regulation of
SIK2 and SIK3 remain to be elucidated. However, the rap-
id decrease in gene and protein expression indicates that
the effect of TNF-α is probably direct, and not secondary
to TNF-induced changes in the expression of other genes.
Since SIK2 and SIK3 expression was lower in insulin-
resistant individuals it is also possible that a functional
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Fig. 5 SIKs promote glucose uptake in human adipocytes and influence
insulin signalling and GLUT4 localisation. SIK isoforms were silenced
using siRNA or inhibited with HG-9-91-01 in adipocytes.
Phosphorylation of HDAC4 at Ser246, normalised to total HDAC4, in
human adipocytes differentiated in vitro, treated with (a) SIK siRNA
(n = 4–8 independent experiments) or (b) HG-9-91-01 (3 μmol/l, over-
night) (n = 3 independent experiments). Glucose uptake at basal (white
bars) and after insulin stimulation (10 nmol/l, black bars) in human adi-
pocytes differentiated in vitro, treated with (c, d) SIK siRNA (n= 4 inde-
pendent experiments performed in triplicate) or (e) HG-9-91-01 (3 μmol/
l, overnight) (n= 3 independent experiments performed in triplicate). To
visualise differences and facilitate statistical analysis, basal glucose up-
take (normalised to siScr-treated cells) and insulin-stimulated glucose
uptake (normalised to cells treated with siScr and insulin) are presented
in (c) and (d), respectively. The stimulation index in these experiments
was about tenfold. (f) Glucose uptake at basal (white bars) and after
insulin stimulation (1 nmol/l, grey bars and 10 nmol/l, black bars) in
human adipocytes differentiated in vitro, treated with HG-9-91-01
(10 μmol/l, 1 h) (n = 4 independent experiments performed in triplicate).
(g) Presence of GLUT4 in the TIRF-zone at basal (white bars) and after
insulin stimulation (0.1 nmol/l, grey bars and 1 nmol/l, black bars) in
primary rat adipocytes treated with HG-9-91-01 (10 μmol/l, 1 h), mea-
sured by immunofluorescence TIRF microscopy (n = 3–5 independent
experiments each in which 30–50 cells per condition were analysed).
Insulin-induced phosphorylation of PKB/Akt at Thr308 (h) and Ser473
(i) normalised to total PKB/Akt, in human adipocytes differentiated
in vitro, treated with HG-9-91-01 (3 μmol/l, overnight) followed by in-
sulin (10 nmol/l, 15 min) (n = 4 independent experiments). Statistical
significance determined by one-way ANOVA with Tukey’s (a) or
Dunnett’s (c, d) multiple comparisons post hoc tests, two-way ANOVA
with Sidak’s (e–g) multiple comparisons post hoc test, and unpaired
Student’s t test (b, h, i). *p < 0.05, **p< 0.01, ***p< 0.001
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A critical question is how the reduced SIK2 and SIK3
expression in obesity impacts adipose tissue physiology.
Previous studies in rodents have proposed that SIKs regulate
glucose uptake in adipocytes [19, 20]. In our study, we dem-
onstrate an important role for SIK isoforms in promoting basal
and insulin-stimulated glucose uptake also in human adipo-
cytes, using both genetic (siRNA) and pharmacological (pan-
SIK inhibition) approaches. Silencing of SIK2 induced com-
pensatory upregulation of SIK1 and SIK3, leading to only a
marginal reduction in total SIK activity, making it difficult to
conclude on the individual role of SIK2. Given the low abun-
dance of SIK3 relative to SIK2 in human adipocytes, at first we
anticipated that the functional contribution of SIK3 would be
much smaller than that of SIK2. However, kinase activity
measurements and siSIK3 treatment revealed that there is a
significant level of SIK3 activity in human adipose tissue that
contributes to the positive effect of SIKs on glucose uptake.
We were not able to achieve silencing of SIK1 at protein level,
making any conclusions about the role of SIK1 uncertain.
When exploring mechanisms for the regulation of glucose
uptake by SIKs we noted that, in contrast tomurine adipocytes
[19, 20], SIK isoforms do not promote GLUT expression in
human adipocytes. Thus, our data suggest that the positive
effect of SIKs on glucose uptake in human adipocytes is not
likely to be mediated by altered protein levels of glucose
transporters. However, the rate of glucose uptake is ultimately
dependent on the number of transporters present on the cell
surface and not the overall cellular levels. Accordingly, our
data suggest that SIKs promote plasma membrane localisation
of GLUT4 in adipocytes. The upstream mechanism involves
positive effects of SIKs on the insulin-induced phosphoryla-
tion and activation of PKB/Akt. The fact that the effect of SIK
inhibition on GLUT4 localisation was smaller than that on
glucose uptake and detected only at a sub-maximal dose of
insulin could be a result of methodological (snapshot vs cu-
mulative assay) and species (rat vs human) differences.
Moreover, since GLUT4 translocation and glucose uptake
were also reduced by SIK inhibition in the basal state we do
not rule out the possibility that additional mechanisms may
contribute. The fact that the ability of insulin to induce these
processes (stimulation index, fold change) was not altered
even though the phosphorylation of PKB/Akt was markedly
blunted indicates that the effect of SIKs on basal glucose up-
take and GLUT4 localisation is probably mediated by a dis-
tinct, yet unknown, mechanism.
An important question to answer in future studies is if the
differential expression of SIKs in adipose tissue plays a causal
role in the development of obesity or insulin resistance
in vivo. Mice with global deficiency of SIK2 displayed no
weight phenotype [20], arguing against a causal relationship
between SIK2 downregulation and obesity. However, it is
quite possible that some effects of SIK2 deficiency are masked
by compensatory mechanisms due to embryonic loss of the
protein or isoform redundancy. Although reduced PKB/Akt
activation might not fully explain the effects we observed on
GLUT4 translocation and glucose uptake in cells, these results
per se, as well as the strong negative association of SIK2
expression with HOMA-IR, suggest that downregulation of
SIK2 and SIK3 in obesity might contribute to the development
of insulin resistance in vivo—at least in adipose tissue. In line
with this, Sik2-/- mice showed some degree of insulin resis-
tance in their adipose tissue [20]. Considering the low expres-
sion level of SIK1 in human adipose tissue, we are not sure of
the physiological relevance of the differential expression of
this isoform in obesity. Previous studies have demonstrated
that Sik1 is upregulated in skeletal muscle, liver and adipose
tissue of obese mice [9, 40] and this has been linked to the
development of insulin resistance [40]. Given the compensa-
tory upregulation of SIK1 that we observed when silencing
SIK2 in adipocytes, it is possible that increased SIK1 expres-
sion in adipose tissue from obese individuals is secondary to
downregulation of SIK2 in these individuals.
In summary, we have demonstrated that SIK2 and SIK3 are
downregulated in human obesity and insulin resistance.
Furthermore, SIKs promote glucose uptake in human adipo-
cytes, at least partly through direct mechanisms. In future
studies it will be important to identify molecular targets of
SIK2 and SIK3 that could be involved in the regulation of
PKB/Akt phosphorylation and GLUT trafficking.
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